Anthony M Casapao

Anthony M Casapao, Pharm.D., M.P.H.

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (904) 244-9129
Business Email: casapao@cop.ufl.edu

About Anthony M Casapao

Anthony M. Casapao received his Doctor of Pharmacy degree from Wingate University in Wingate, North Carolina. He then pursued post-graduate training at St. Vincent’s Medical Center in Jacksonville, Florida, by completing an American Society of Health-System Pharmacists, or ASHP, -accredited pharmacy practice residency. Casapao continued his post-graduate training at University of Pittsburgh Medical Center in Pennsylvania, completing an ASHP-accredited specialty practice residency in infectious diseases. Upon completion of his residency, he maintained his interest in infectious diseases and pursued an American College of Clinical Pharmacy peer reviewed pharmacotherapy fellowship in infectious diseases and health outcomes. After achieving five years post-graduate training, Casapao served as an assistant professor in the department of pharmacy practice at Husson University School of Pharmacy in Bangor, Maine. Casapao joined the University of Florida in October 2017, as a clinical assistant professor in the department of pharmacotherapy and translational research.

Board Certifications

  • Infectious Diseases Pharmacotherapy (BCIDP)
    Board of Pharmacy Specialties

Research Profile

Casapao’s research interest focuses on pharmacoepidemiology, antimicrobial resistance and health outcomes. Specifically, he is interested in the clinical implications in anti-infective resistance, using stochastic modeling to determine appropriate antibiotic selection and infectious diseases surveillance and epidemiology.

Open Researcher and Contributor ID (ORCID)

0000-0003-0501-3110

Publications

2021
Comparison of acute kidney injury in patients prescribed vancomycin in combination with piperacillin–tazobactam or cefepime for diabetic foot infections
Journal of Investigative Medicine. 69(4):893-896 [DOI] 10.1136/jim-2020-001594.
2021
Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Tests on Antimicrobial Prescribing for Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Escherichiacoli and Klebsiellapneumoniae in Bloodstream Infection
Microbiology Spectrum. 9(2) [DOI] 10.1128/spectrum.00464-21.
2021
Preanalytical Challenges During Capillary Fingerstick Sampling Preclude Its Widespread Use in Adult Hospitalized Patients.
American journal of clinical pathology. 155(3):412-417 [DOI] 10.1093/ajcp/aqaa138. [PMID] 33009571.
2020
“Pet Nemo’s Pills”: The Last Loophole in Antimicrobial Stewardship?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 70(1):177-179 [DOI] 10.1093/cid/ciz388. [PMID] 31074491.
2020
An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Clinical therapeutics. 42(4):692-702 [DOI] 10.1016/j.clinthera.2020.01.023. [PMID] 32147146.
2020
Community-Acquired Pneumonia (CAP)
PharmacotherapyFirst: A Multimedia Learning Resource. [DOI] 10.21019/pharmacotherapyfirst.cap_overview.
2020
Interactive Case: Combination Antibiotics for Staphylococcus aureus
Infectious Diseases Self-Assessment Program 2020 Book 2 Resistant Gram-Positive Infections. 2:171-180
2019
Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter?
Antimicrobial agents and chemotherapy. 63(3) [DOI] 10.1128/AAC.02211-18. [PMID] 30617094.
2019
Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis.
Infectious diseases and therapy. 8(4):671-686 [DOI] 10.1007/s40121-019-00259-4. [PMID] 31392580.
2019
Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.
Infectious diseases and therapy. 8(2):199-208 [DOI] 10.1007/s40121-019-0242-5. [PMID] 30915685.
2019
Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It’s Complicated.
Infectious diseases and therapy. 8(4):627-640 [DOI] 10.1007/s40121-019-00268-3. [PMID] 31637596.
2018
Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study.
Antimicrobial agents and chemotherapy. 62(1) [DOI] 10.1128/AAC.01464-17. [PMID] 29109159.
2018
Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections.
Infectious diseases and therapy. 7(1):161-169 [DOI] 10.1007/s40121-018-0187-0. [PMID] 29470836.
2017
Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
Pharmacotherapy. 37(11):1347-1356 [DOI] 10.1002/phar.2034. [PMID] 28949410.
2017
Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Antimicrobial agents and chemotherapy. 61(2) [DOI] 10.1128/AAC.02015-16. [PMID] 27895012.
2016
Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion.
Hospital practice (1995). 44(4):183-189 [PMID] 27598313.
View on: PubMed
2016
Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections.
American journal of infection control. 44(8):917-21 [DOI] 10.1016/j.ajic.2016.02.017. [PMID] 27079241.
2016
Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Antimicrobial agents and chemotherapy. 60(10):5841-8 [DOI] 10.1128/AAC.00227-16. [PMID] 27431221.
2015
Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
Antimicrobial agents and chemotherapy. 59(6):2978-85 [DOI] 10.1128/AAC.03970-14. [PMID] 25753631.
2015
Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.
Antimicrobial agents and chemotherapy. 59(4):1969-76 [DOI] 10.1128/AAC.04141-14. [PMID] 25605354.
2014
Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
Clinical therapeutics. 36(10):1317-33 [DOI] 10.1016/j.clinthera.2014.05.061. [PMID] 25017183.
2014
Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy. 58(8):4636-41 [DOI] 10.1128/AAC.02820-13. [PMID] 24890596.
2014
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
Antimicrobial agents and chemotherapy. 58(5):2541-6 [DOI] 10.1128/AAC.02371-13. [PMID] 24550331.
2013
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
The Journal of antimicrobial chemotherapy. 68(12):2921-6 [DOI] 10.1093/jac/dkt294. [PMID] 23928022.
2013
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.
Antimicrobial agents and chemotherapy. 57(9):4252-4259 [DOI] 10.1128/AAC.00380-13. [PMID] 23796929.
2013
Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
Antimicrobial agents and chemotherapy. 57(9):4190-6 [DOI] 10.1128/AAC.00526-13. [PMID] 23774437.
2012
Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Expert opinion on pharmacotherapy. 13(8):1177-86 [DOI] 10.1517/14656566.2012.685718. [PMID] 22594846.

Education

M.P.H.
2018 · Harvard University
PGY2 Infectious Diseases Residency
2010-2011 · University of Pittsburgh Medical Center
PGY1 Pharmacy Practice Residency
2009-2010 · St. Vincent’s Medical Center
Pharm.D.
2009 · Wingate University
B.S.
2005 · Midwestern University

Teaching Profile

Courses Taught
2018-2020
PHA5755 Micro, Immun, Virol
2018-2021
PHA5605 Infectious Disease
2019
PHA5026C Personal and Professional Development VI
2018-2019
PHA5166L Prof Skills Lab Vi
2018
PHA5165L Prof Skills Lab V
2018
PHA5788 Pharmacotherapy 6
2021
PHA5733 Year 2 Enhancement
2021
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology

Contact Details

Phones:
Business:
(904) 244-9129
Emails: